There is nothing like a bit of recognition to energize your efforts, right? Promega was recently awarded the 2019 Distinguished Performer: Sustainabilityaward, as one of the Deloitte Wisconsin 75 awardees.
This award is not so much a feather in our cap, as fuel for our sustainability fire both in Madison, and globally. Here are a few details on the award and why Promega was chosen.
In the fall of 1989, a small group of forensic scientists, law enforcement officials and representatives from Promega Corporation gathered in Madison, Wisconsin, for the very first International Symposium on Human Identification (ISHI). At the time, DNA typing was in its infancy and had not yet been validated as a forensic method. The available technology consisted of two methods: detection of restriction fragment length polymorphisms (RFLPs) and variable number of tandem repeats (VNTRs). Promega had developed products based on both analytical methods, which essentially provide a DNA “fingerprint” or profile for each individual tested.
Among the attendees at that first symposium was Tom Callaghan, then a graduate student. That experience made a significant impact on his career path. Last week, at ISHI 30, he presented a session on rapid DNA testing. Dr. Callaghan currently serves as a Senior Biometric Scientist for the FBI. In 1999, he was instrumental in launching the FBI’s Combined DNA Index System (CODIS) and in 2003, he became the first CODIS Unit Chief.
Joe Willie Smith has always been a creator. As a young child growing up in Milwaukee, his mother encouraged him to make art and find beauty in the everyday. Following years of work in printing and graphic design (including posters for Gil-Scott Heron and Chaka Khan), Smith began channeling his inspiration and creativity into building playable “sonic sculptures” out of found objects. “They’re not all considered instruments…sometimes I just make soundscapes out of them,” Smith says.
As the artist-in-residence for the Promega Fall Art Showcase, Smith set out to create a sonic sculpture from collected items from the Promega campus. He planned to perform on the instrument at the opening of the Art Show, but his creative process led to something much more—a collaborative experience in sound and color.
Promega Corporation today was named one of the “Best Places to Work” in the greater Madison area in Madison Magazine’s annual survey. Promega ranks fifth in the category of large companies with 101+ employees. The “Best Places to Work 2019” list includes 30 local workplaces.
“We are honored to be recognized among these great Madison companies that clearly value their employees and put people first,” says Gayle Paul, Director of Human Resources Operations at Promega. “Nurturing a work environment and culture that allows each person who works at Promega to realize their full potential benefits not only our business and customers, but also each employee, their families and our community as a whole.”
Are you looking for your Best Place to Work? Explore the career opportunities on our website.
The CEDA awards program of the Wisconsin Economic Development Association recognizes businesses, projects and organizations that are making significant contributions to Wisconsin’s economy. Last week Promega won the Business Retention and Expansion award. short.url/aBcXyZ
With average sea surface temperatures increasing around the world, coral bleaching events are growing in extent and severity. More than two thirds of the corals in the Great Barrier Reef, the world’s largest coral reef, have already bleached. While the physiological consequences of coral bleaching are well-studied, we still don’t fully understand how bleaching happens on a cellular level.
Steve Palumbi at Stanford University is delving deeper into the mechanisms by which coral bleaching occurs. In 2018, Promega pledged $3 million over three years to the nonprofit Revive & Restore Catalyst Science Fund, to identify and develop advanced techniques for conservation, enhancing biodiversity, and genetic rescue. Palumbi was awarded the first grant from this fund to study the genomic stress trigger that causes corals to bleach in warming oceans.
This past May (2019) the symposium “Psychedelic Therapy in Society: Exploring the Mechanisms of Action and Delivery of Care” was hosted by the International Forum on Consciousness at the BioPharmaceutical Technology Center on the Promega Madison Campus.
Having the good fortune to work across the street at Promega, I was able to attend this two-day conference and learn from leading researchers in psychedelics and about their use in therapy.
My interest in psychedelics is relatively new. I didn’t experiment with these substances during high school or college years. But in recent years, I’ve seen a close relative struggle with profound anxiety related to terminal disease, and another with substance abuse and depression. The lessons learned from each experience is that the battery of medicines used to treat such illness can result in additional problems for which there are currently not good medication options. And in some cases, traditional medications can cause further health problems. Continue reading “Psychedelics as Therapeutic Agents: Current Research, Potential Benefits”
Sunscreen usage is increasing, with more people using SPF to prevent the very real threats of skin cancer and early signs of aging. While slathering on the sunscreen is unarguably important to protect your skin from the sun, new concerns arise linking sunscreen chemicals to coral reef bleaching, as an estimated “14,000 tons of sunscreen is believed to be deposited in the oceans annually.”
Coral reefs are the most productive marine ecosystem known. Coral reefs protect coastlines from storm surge and support commercial and recreational fisheries and tourism. Unfortunately, certain chemicals in sunscreen are causing coral reefs to bleach; thus, becoming more susceptible to viral infections. The reefs eventually turn white and die. Coral reef bleaching is the leading cause of coral reef deaths worldwide. This conversation is an important one to discuss leading up to the celebration of World Oceans Day on June 8.
Chemical recreational sunscreen contains oxybenzone, a toxic synthetic molecule. Oxybenzone is prevalent in the majority of mainstream sunscreen brands. This ingredient results in extreme harm to marine organisms. The Ocean Foundation emphasized that, “A single drop of this compound in more than 4 million gallons of water is enough to endanger organisms.” Even if you do not physically go in the water, the chemical can be washed into the ocean through the sand.
In response to this issue, many countries and resorts are banning “reef-toxic” sunscreen. Hawaii and Key West recently passed a bill banning the sale and distribution of any sunscreen that contains 10 toxic ingredients, including oxybenzone. This bill goes into effect January 2021. Many dermatologists are concerned for public safety, highlighting that banning certain sunscreens will decrease overall use. Unprotected sun exposure it the most preventable risk factor for skin cancer. From the perspective of a customer, it is important to be actively informed on what constitutes a “reef-safe” sunscreen. Oxybenzone can pop-up in many moisturizers, primers, and foundations that contain SPF. Reef-friendly options include: any version of chemical sunscreen that does not contain oxybenzone.
With a commitment to protect the environment, Promega has pledged $3 million over the next three years to the Revive and Restore Catalyst Science fund. Organization founders and scientists are focused on an extremely long-term view of wildlife conservation. This fund invests in proof-of-concept research projects that offer innovative solutions for conservation challenges and threatened ecosystems. Marine biologist Steve Palumbi was awarded the first Fund grant to investigate the triggers that may cause corals to bleach. Palumbi reflects on his research in an interview with Stanford News stating, “The report reflects a sense of urgency. We need to start helping corals now, so that as the climate gets worse—and it will inevitably get worse—we’re a little bit in front of the problem. There’s this amazing sense that we all have to just jump in and try ideas and fail so that, eventually, someone comes up with the answers we need.”
On October 9, the 2018 Wisconsin Biohealth Summit was held in Madison, WI, hosted by BioForward, an organization that supports the growth of the biohealth industry in the state. This day-long event covered topics such as how diversifying your team can build better leadership, discovering new markets for existing products, and biomanufacturing. One of the panels on the schedule was “Examining the Economic Impact of Wisconsin’s Biohealth Industry,” and Penny Patterson, our Vice President of Communications, was one of the panel participants. We spoke after the summit to learn what came out of the panel discussion and the topics of interest raised by the biohealth industry attendees.
As we talked, Penny explained many topics were discussed, but ultimately focused around how to attract talented individuals to the biohealth industry in Wisconsin. This concern stemmed in part from the lower profile of the biohealth industry in Wisconsin compared to the more prominent and well-known East and West coasts. Of note, education and quality of life are important tools for recruiting candidates to join the biohealth industry. Continue reading “Finding Its Place: The Biohealth Industry in Wisconsin”
The 2018 Nobel Prize in Physiology and Medicine was awarded to James P. Allison of the United States and Tasuku Honjo of Japan for their work to identify pathways in the immune system that can be used to attack cancer cells (1). Although immunotherapy for cancer has been a goal for many decades, Dr. Allison and Dr. Honjo succeeded through their manipulation of “checkpoint inhibitor” pathways to target cancer cells.
Immune checkpoint inhibitor drugs have been effective in cancers such as aggressive metastatic melanoma, some lung cancers, kidney, bladder and head and neck cancers. These therapies have succeeded in pushing many aggressive cancers below detectable limits, though these cases are notably not relapse-free or necessarily “cured” (2,3).
One challenge in implementing immunotherapy in a cancer treatment regime is the need to understand the genetic makeup of the tumor. Certain tumors, with specific genetic features, are far more likely to respond to immune checkpoint therapy than others. For this reason, Microsatellite Instability (MSI) analysis has become an increasingly relevant tool in genetic and immuno-oncology research.